US stocks are abnormal | Oral weight loss drug Orforglipron succeeded in Phase III trial, and Lilly (LLY.US) rose more than 3% at one point.

According to the Wise Finance APP, on Thursday, Eli Lilly's (LLY.US) stock price rose more than 3% at one point, but as of the time of writing, the stock price has narrowed to 1.84%, reaching $1061. On the news front, the company announced that its oral weight loss drug orforglipron showed superior weight maintenance effects compared to the control in a Phase III clinical trial, suitable for obese or overweight adults who have previously used injectable weight loss drugs (including the company's own Zepbound and Novo Nordisk's Wegovy).